Trials / Completed
CompletedNCT01451619
A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)
A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study to Assess the Pharmacodynamics of MK-0524 in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea. (Protocol No. 155)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the effect of MK-0524 relative to placebo, on signs and symptoms of rosacea and to determine the safety and tolerability profile of MK-0524 in participants with rosacea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Laropiprant | One 100-mg tablet orally once daily for 4 weeks |
| DRUG | Placebo for Laropiprant | One tablet orally once daily for 4 weeks |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2011-10-13
- Last updated
- 2015-03-25
Source: ClinicalTrials.gov record NCT01451619. Inclusion in this directory is not an endorsement.